R
Robert H. Shoemaker
Researcher at National Institutes of Health
Publications - 216
Citations - 23122
Robert H. Shoemaker is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cancer & DNA damage. The author has an hindex of 55, co-authored 197 publications receiving 21697 citations. Previous affiliations of Robert H. Shoemaker include University of Bologna & Strong Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells
George L. Scheffer,M C de Jong,A Monks,M. J. Flens,C D Hose,Miguel Izquierdo,Robert H. Shoemaker,R.J. Scheper +7 more
TL;DR: Drug resistant tumour cells may, by having elevated levels of major histocompatibility complex related molecules, be particular good candidates for alternative therapeutic therapies, such as cytotoxic T cell mediated immune-therapies.
Journal ArticleDOI
12 Arylstibonic acids that inhibit the DNA binding of five B-ZIP dimers.
Vikas Rishi,Won-Jun Oh,Sarah L. Heyerdahl,Jianfei Zhao,Dominic A. Scudiero,Robert H. Shoemaker,Charles Vinson +6 more
TL;DR: A panel of 14 additional arylstibonic acid derivatives of NSC13778 are examined for their ability to inhibit the DNA binding of five B-ZIP dimers (c-Fos|JunD, VBP, C/EBPalpha, C-EBPbeta, and CREB) and some compounds specifically inhibit DNA binding, with VBP and c-FOS| JunD being most easily disrupted.
Book ChapterDOI
Human Tumour Xenograft Models for Use with an In Vitro-Based, Disease-Oriented Antitumour Drug Screening Program
Robert H. Shoemaker,Theodore L. McLemore,B. J. Abbott,D. L. Fine,E. Gorelik,Joseph G. Mayo,Øystein Fodstad,Michael R. Boyd +7 more
TL;DR: Rational application of these longer-term models with particular attention to modeling of in situ vascular barriers, tumor microenvironment, and the natural history of the target diseases may facilitate identification and development of new drugs with significant clinical activity against the common adult solid tumors.
Journal ArticleDOI
Separation and SAR Study of HIF-1α Inhibitory Tubulosines from Alangium cf. longiflorum
Paul Klausmeyer,Thomas G. McCloud,Badarch Uranchimeg,Giovanni Melillo,Dominic A. Scudiero,John H. Cardellina,Robert H. Shoemaker +6 more
TL;DR: A crude organic solvent extract of Alangium cf.
Journal ArticleDOI
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells
Sarah L. Heyerdahl,Julian M. Rozenberg,Louis Jamtgaard,Vikas Rishi,Lyuba Varticovski,Kelly Akah,Dominic A. Scudiero,Robert H. Shoemaker,Tatiana S. Karpova,Richard O. Day,James G. McNally,Charles Vinson +11 more
TL;DR: The arylstibonic acid compound was cytostatic in clear cell sarcoma cells, which express a chimera between the B-ZIP domain of ATF-1 and N-terminal activation domain of EWS but not in K562 cells that express a non-B- ZIP containing chimeric protein BCR-ABL.